Radisens Diagnostics has been awarded a €1 million contract to develop a blood testing device for the European Space Agency (ESA).
The technology developed for the space programme by Radisens Diagnostics will enable a general physician (GP) to take a finger-prick of blood and test patients for diabetes, heart disease, liver and kidney damage and thyroid conditions in their surgery with instant results. Future developments will enable the diagnosis of heart attacks, early stage cancers such as prostate and ovarian, infectious diseases such as HIV, and viruses.
Currently, if a person needs a blood test they have to be referred to a hospital where a qualified phlebotomist takes a vial(s) of blood which has to be sent to a central laboratory for testing. The whole process introduces significant delays, patient anxiety and huge inefficiencies within healthcare systems, for what are routine tests.
Jerry O’Brien, CEO Radisens Diagnostics, said: "Winning this contract from the European Space Agency is a significant endorsement of our ‘sample-to-answer’ device and the breadth of blood tests it can offer. We are delighted to formalise our strategic partnership with ESA with the support of Enterprise Ireland and look forward to working on the application of our technology to terrestrial and space healthcare diagnostic needs."
TechCentral Reporters
Subscribers 0
Fans 0
Followers 0
Followers